Gilead Sciences Expands Licensing Agreements for HIV Treatment

09:06 AM EDT, 09/16/2026 (MT Newswires) -- Gilead Sciences (GILD) has expanded the scope of its six royalty-free lenacapavir voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis, aiming to help enable sustainable access for the drug to communities impacted by the disease, the company said Wednesday. The agreements cover 120 countries with high incidence of HIV and will support manufacturing readiness, technology transfer, and future supply planning while the phase 3 trial for the drug is ongoing, Gilead said. The six voluntary licensing partners who are currently manufacturing twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis are Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Eva Pharma for Pharmaceutical Industries, Ferozsons Laboratories, Hetero and Viatris (VTRS) subsidiary Mylan Laboratories, according to a statement.